| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accuracy of Inchworm Sign on Diffusion-Weighted MRI in Differentiating Muscle-Invasive Bladder Cancer
|
Kazan, Huseyin Ozgur
|
|
|
|
1 |
p. 35-44
|
artikel
|
| 2 |
A More Thorough Transurethral Resection
|
Messing, Edward M.
|
|
2017
|
|
1 |
p. 75-77
|
artikel
|
| 3 |
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer
|
Hof, Jasper P.
|
|
|
|
1 |
p. 59-71
|
artikel
|
| 4 |
Antibiotics and BCG
|
Messing, Edward M.
|
|
|
|
1 |
p. 97-99
|
artikel
|
| 5 |
Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?
|
Breyer, Johannes
|
|
2017
|
|
1 |
p. 31-34
|
artikel
|
| 6 |
Assessment of a European Bladder Cancer Predictive Model for Non-Muscle Invasive Bladder Cancer in an Australian Cohort
|
Alberto, Matthew
|
|
2019
|
|
1 |
p. 31-38
|
artikel
|
| 7 |
Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab
|
Tan, Eugene
|
|
|
|
1 |
p. 81-88
|
artikel
|
| 8 |
BcCluster: A Bladder Cancer Database at the Molecular Level
|
Bhat, Akshay
|
|
2016
|
|
1 |
p. 65-76
|
artikel
|
| 9 |
BCG in Immunocompromised Patients: Is it effective? Is it safe?
|
Messing, Edward M.
|
|
|
|
1 |
p. 89-91
|
artikel
|
| 10 |
BCG versus Cystectomy for High Risk, High Grade Non Muscle Invasive Bladder Cancer
|
Messing, Edward M.
|
|
|
|
1 |
p. 107-108
|
artikel
|
| 11 |
Bladder Cancer Health Literacy: Assessing Readability of Online Patient Education Materials
|
Powell, Lauren E.
|
|
|
|
1 |
p. 91-98
|
artikel
|
| 12 |
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
|
Lerner, Seth P.
|
|
2016
|
|
1 |
p. 37-47
|
artikel
|
| 13 |
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis
|
Westhoff, Ellen
|
|
2018
|
|
1 |
p. 91-112
|
artikel
|
| 14 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2018
|
|
1 |
p. 129-130
|
artikel
|
| 15 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2019
|
|
1 |
p. 81-82
|
artikel
|
| 16 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2017
|
|
1 |
p. 73
|
artikel
|
| 17 |
Challenging Cases in Urothelial Cancer1
|
Soloway, Mark S.
|
|
|
|
1 |
p. 91-92
|
artikel
|
| 18 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
|
|
1 |
p. 113
|
artikel
|
| 19 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
|
|
1 |
p. 115
|
artikel
|
| 20 |
Challenging Cases in Urothelial Cancer: Case 19
|
Soloway, Mark S.
|
|
|
|
1 |
p. 99-102
|
artikel
|
| 21 |
Challenging Cases in Urothelial Cancer: Case 17
|
Soloway, Mark S.
|
|
|
|
1 |
p. 117
|
artikel
|
| 22 |
Challenging Cases in Urothelial Cancer: Case 18
|
Soloway, Mark S.
|
|
|
|
1 |
p. 119
|
artikel
|
| 23 |
Challenging Cases in Urothelial Cancer: Case 23
|
Soloway, Mark S.
|
|
|
|
1 |
p. 89-92
|
artikel
|
| 24 |
Challenging Cases in Urothelial Cancer: Case 27
|
Soloway, Mark S.
|
|
|
|
1 |
p. 97-100
|
artikel
|
| 25 |
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer
|
Soloway, Mark S.
|
|
|
|
1 |
p. 93-103
|
artikel
|
| 26 |
Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
|
Zargar, Homayoun
|
|
2017
|
|
1 |
p. 57-63
|
artikel
|
| 27 |
Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years
|
Raghavan, Derek
|
|
2015
|
|
1 |
p. 3-13
|
artikel
|
| 28 |
Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
|
Soares, Adriana
|
|
|
|
1 |
p. 1-8
|
artikel
|
| 29 |
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
|
|
|
2015
|
|
1 |
p. 29-30
|
artikel
|
| 30 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
2019
|
|
1 |
p. 83-84
|
artikel
|
| 31 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
2018
|
|
1 |
p. 133-136
|
artikel
|
| 32 |
Clinical Trials Corner
|
|
|
2016
|
|
1 |
p. 119-121
|
artikel
|
| 33 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
|
|
1 |
p. 93-95
|
artikel
|
| 34 |
Clinical Trials Corner Issue 7(1)
|
Agarwal, Piyush K.
|
|
|
|
1 |
p. 103-106
|
artikel
|
| 35 |
Clinical Trials Corner Issue 8(1)
|
Agarwal, Piyush K.
|
|
|
|
1 |
p. 93-95
|
artikel
|
| 36 |
Clinical Trials Corner Issue 9(1)
|
Agarwal, Piyush K.
|
|
|
|
1 |
p. 101-103
|
artikel
|
| 37 |
Clinical Trials Corner Issue 10(1)
|
Agarwal, Piyush K.
|
|
|
|
1 |
p. 83-87
|
artikel
|
| 38 |
Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)
|
Power, Nicholas E.
|
|
2016
|
|
1 |
p. 27-36
|
artikel
|
| 39 |
Comparison of Health-Related Quality of Life Between Japanese and American Patients with Bladder Cancer as Measured by a Newly Developed Japanese Version of the Bladder Cancer Index
|
Osawa, Takahiro
|
|
|
|
1 |
p. 61-69
|
artikel
|
| 40 |
Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study
|
Passoni, Niccolò M.
|
|
2016
|
|
1 |
p. 91-99
|
artikel
|
| 41 |
Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7
|
Bolenz, Christian
|
|
2018
|
|
1 |
p. 67-75
|
artikel
|
| 42 |
Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer
|
Garg, Tullika
|
|
2018
|
|
1 |
p. 121-128
|
artikel
|
| 43 |
Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer
|
Matulewicz, Richard S.
|
|
2017
|
|
1 |
p. 45-49
|
artikel
|
| 44 |
Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer
|
Farber, Nicholas J.
|
|
2018
|
|
1 |
p. 113-120
|
artikel
|
| 45 |
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
|
Drakaki, Alexandra
|
|
|
|
1 |
p. 43-52
|
artikel
|
| 46 |
Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer?
|
Al-Hogbani, Mofarej
|
|
|
|
1 |
p. 63-69
|
artikel
|
| 47 |
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?
|
Messing, Edward M.
|
|
|
|
1 |
p. 105-107
|
artikel
|
| 48 |
Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?
|
Niegisch, Günter
|
|
2015
|
|
1 |
p. 97-103
|
artikel
|
| 49 |
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma
|
Nelson, Ariel A.
|
|
|
|
1 |
p. 33-42
|
artikel
|
| 50 |
Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model
|
Creswell, Michael L.
|
|
|
|
1 |
p. 87-96
|
artikel
|
| 51 |
Editorial
|
Lerner, Seth P.
|
|
2015
|
|
1 |
p. 1
|
artikel
|
| 52 |
Editorial concerning “Pelvic lymph node dissection may be limited on the contralateral side in strictly unilateral bladder cancer without compromising oncological radicality”
|
|
|
2016
|
|
1 |
p. 61-62
|
artikel
|
| 53 |
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”
|
Kiemeney, Lambertus A.L.M.
|
|
|
|
1 |
p. 83-85
|
artikel
|
| 54 |
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy
|
Durant, Adri M.
|
|
|
|
1 |
p. 35-45
|
artikel
|
| 55 |
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review
|
Grant, Michael J.
|
|
|
|
1 |
p. 9-23
|
artikel
|
| 56 |
Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients
|
Li, Roger
|
|
2017
|
|
1 |
p. 65-71
|
artikel
|
| 57 |
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer
|
McConkey, David J.
|
|
|
|
1 |
p. 1-8
|
artikel
|
| 58 |
Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer
|
Vo, Amanda X.
|
|
|
|
1 |
p. 53-60
|
artikel
|
| 59 |
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder
|
Menbari Oskouie, Iman
|
|
|
|
1 |
p. 47-59
|
artikel
|
| 60 |
Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique
|
Flack, Chandra K.
|
|
2015
|
|
1 |
p. 73-79
|
artikel
|
| 61 |
High-throughput DNA Sequencing Identifies Novel CtIP (RBBP8) Variants in Muscle-invasive Bladder Cancer Patients
|
Jevons, Sarah J.
|
|
2015
|
|
1 |
p. 31-44
|
artikel
|
| 62 |
Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy
|
Boström, P.J.
|
|
2016
|
|
1 |
p. 101-109
|
artikel
|
| 63 |
Identification of a Novel Ferroptosis-Related Gene Signature for Prediction of Prognosis in Bladder Urothelial Carcinoma
|
Shi, Xiaokai
|
|
|
|
1 |
p. 19-34
|
artikel
|
| 64 |
Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model
|
Chand, Damini
|
|
2019
|
|
1 |
p. 63-71
|
artikel
|
| 65 |
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
|
Sherif, Amir
|
|
2018
|
|
1 |
p. 1-7
|
artikel
|
| 66 |
Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?
|
Buchwald, Zachary S.
|
|
2015
|
|
1 |
p. 15-27
|
artikel
|
| 67 |
Implementation of a Reduced Opioid Utilization Protocol for Radical Cystectomy
|
Greenberg, Daniel R.
|
|
|
|
1 |
p. 33-42
|
artikel
|
| 68 |
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
|
Holmsten, Karin
|
|
|
|
1 |
p. 71-80
|
artikel
|
| 69 |
Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response
|
Grotenhuis, Anne J.
|
|
2016
|
|
1 |
p. 77-89
|
artikel
|
| 70 |
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
|
Bidnur, S.
|
|
2016
|
|
1 |
p. 15-25
|
artikel
|
| 71 |
Intravesical Coxsackievirus A21 Therapy for Non-Muscle Invasive Bladder Cancer
|
Messing, Edward
|
|
|
|
1 |
p. 97-98
|
artikel
|
| 72 |
Intravesical Therapy – BCG and Beyond
|
Grossman, H. Barton
|
|
2019
|
|
1 |
p. 73-80
|
artikel
|
| 73 |
Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?
|
Rozanski, Alexander T.
|
|
2015
|
|
1 |
p. 91-96
|
artikel
|
| 74 |
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?
|
Mehr, Justin P.
|
|
|
|
1 |
p. 41-48
|
artikel
|
| 75 |
Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions
|
Zuniga, Kyle B.
|
|
|
|
1 |
p. 9-23
|
artikel
|
| 76 |
Limited Funds for Bladder Cancer Research and What Can We Do About It
|
Boormans, Joost L.
|
|
2016
|
|
1 |
p. 49-51
|
artikel
|
| 77 |
Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort
|
Grigg, Claud M.
|
|
|
|
1 |
p. 83-90
|
artikel
|
| 78 |
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
|
Todenhöfer, Tilman
|
|
2018
|
|
1 |
p. 19-29
|
artikel
|
| 79 |
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
|
Gershman, Boris
|
|
2015
|
|
1 |
p. 1-14
|
artikel
|
| 80 |
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer
|
Abbosh, Philip H.
|
|
2018
|
|
1 |
p. 9-18
|
artikel
|
| 81 |
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
|
|
|
|
|
1 |
p. 109
|
artikel
|
| 82 |
Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
|
Tamura, Shuzo
|
|
2018
|
|
1 |
p. 77-90
|
artikel
|
| 83 |
Molecular Landscape of Non-Muscle Invasive Bladder Cancer
|
Messing, Edward M.
|
|
2018
|
|
1 |
p. 131-132
|
artikel
|
| 84 |
Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer
|
Steinberg, Ryan L.
|
|
2019
|
|
1 |
p. 39-49
|
artikel
|
| 85 |
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays
|
Heard, John R.
|
|
|
|
1 |
p. 71-81
|
artikel
|
| 86 |
Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx
|
|
|
|
|
1 |
p. 111-112
|
artikel
|
| 87 |
Paper Alert
|
Messing, Edward M.
|
|
2016
|
|
1 |
p. 123-125
|
artikel
|
| 88 |
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors1
|
Chandi, Jobin
|
|
|
|
1 |
p. 61-69
|
artikel
|
| 89 |
Pelvic Lymph Node Dissection may be Limited on the Contralateral Side in Strictly Unilateral Bladder Cancer without Compromising Oncological Radicality
|
Kiss, Bernhard
|
|
2016
|
|
1 |
p. 53-59
|
artikel
|
| 90 |
Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
|
Walker, Melanie
|
|
2018
|
|
1 |
p. 49-65
|
artikel
|
| 91 |
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
|
Abida, Wassim
|
|
2016
|
|
1 |
p. 111-117
|
artikel
|
| 92 |
Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
|
Diamantopoulos, Leonidas N.
|
|
|
|
1 |
p. 71-81
|
artikel
|
| 93 |
Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study
|
Schmitz-Dräger, Claudia
|
|
|
|
1 |
p. 25-33
|
artikel
|
| 94 |
Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer
|
Reiß, Julian
|
|
|
|
1 |
p. 71-78
|
artikel
|
| 95 |
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer
|
Einerhand, Sarah M.H.
|
|
|
|
1 |
p. 49-57
|
artikel
|
| 96 |
Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
|
Martin, Susan
|
|
|
|
1 |
p. 45-53
|
artikel
|
| 97 |
Quality of Life and Health State Utilities in Bladder Cancer
|
Smith, Angela B.
|
|
|
|
1 |
p. 55-70
|
artikel
|
| 98 |
Readmission Rate and Causes at 90-Day after Radical Cystectomy in Patients on Early Recovery after Surgery Protocol
|
Altobelli, Emanuela
|
|
2017
|
|
1 |
p. 51-56
|
artikel
|
| 99 |
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors
|
Guo, Charles C.
|
|
|
|
1 |
p. 1-14
|
artikel
|
| 100 |
Recovering from Cystectomy: Patient Perspectives
|
McMullen, Carmit K.
|
|
2019
|
|
1 |
p. 51-61
|
artikel
|
| 101 |
Reply from Authors to the Editorial Comment
|
Kiss, Bernhard
|
|
2016
|
|
1 |
p. 63-64
|
artikel
|
| 102 |
Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review
|
Li, Roger
|
|
2018
|
|
1 |
p. 31-40
|
artikel
|
| 103 |
Salvage Hyperthermic Gemcitabine and Docetaxel Combination Chemotherapy After BCG Failure in Non-Muscle Invasive Bladder Cancer Patients
|
Rao, Mounica Y.
|
|
|
|
1 |
p. 25-32
|
artikel
|
| 104 |
Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple?
|
Roghmann, Florian
|
|
|
|
1 |
p. 1-4
|
artikel
|
| 105 |
Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
|
Steinberg, Ryan L.
|
|
2015
|
|
1 |
p. 65-72
|
artikel
|
| 106 |
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells
|
Shao, Yong
|
|
|
|
1 |
p. 29-40
|
artikel
|
| 107 |
Smoking Cessation in Bladder Cancer Patients
|
Messing, Edward M.
|
|
2019
|
|
1 |
p. 85-86
|
artikel
|
| 108 |
Statins are Associated with Reduced Overall and Cancer-Specific Mortality in Patients Undergoing Radical Cystectomy for Bladder Cancer
|
Wissing, Michel D.
|
|
|
|
1 |
p. 53-62
|
artikel
|
| 109 |
Surface Labeling with Adhesion Protein FimH Improves Binding of Immunotherapeutic Agent Salmonella Ty21a to the Bladder Epithelium
|
Burggraaf, Maroeska J.
|
|
|
|
1 |
p. 79-90
|
artikel
|
| 110 |
Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials
|
Folgosa Cooley, Lauren
|
|
|
|
1 |
p. 23-31
|
artikel
|
| 111 |
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
|
Benkhadra, Raed
|
|
|
|
1 |
p. 5-17
|
artikel
|
| 112 |
Systematic Review: Targeting HER2 in Bladder Cancer
|
Koshkin, Vadim S.
|
|
2019
|
|
1 |
p. 1-12
|
artikel
|
| 113 |
Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions
|
Frantzi, Maria
|
|
2017
|
|
1 |
p. 1-18
|
artikel
|
| 114 |
Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer
|
Koti, Madhuri
|
|
2018
|
|
1 |
p. 137
|
artikel
|
| 115 |
The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study1
|
Faessen, Janine P.M.
|
|
|
|
1 |
p. 73-82
|
artikel
|
| 116 |
The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy
|
Suzuki, Hiroaki
|
|
|
|
1 |
p. 13-21
|
artikel
|
| 117 |
The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum
|
Liu, Nick W.
|
|
2019
|
|
1 |
p. 13-19
|
artikel
|
| 118 |
The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer
|
Dancik, Garrett M.
|
|
2015
|
|
1 |
p. 45-63
|
artikel
|
| 119 |
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus
|
Joo, Kwan Joong
|
|
2015
|
|
1 |
p. 81-90
|
artikel
|
| 120 |
The Rationale for Post-Operative Radiation in Localized Bladder Cancer
|
Baumann, Brian C.
|
|
2017
|
|
1 |
p. 19-30
|
artikel
|
| 121 |
Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC)
|
Kleinmann, Nir
|
|
2019
|
|
1 |
p. 21-29
|
artikel
|
| 122 |
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence
|
Asimakopoulos, Anastasios D.
|
|
|
|
1 |
p. 15-27
|
artikel
|
| 123 |
Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation
|
Russo, Ilaria J.
|
|
2018
|
|
1 |
p. 41-48
|
artikel
|
| 124 |
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment
|
Meeks, Joshua J.
|
|
|
|
1 |
p. 1-11
|
artikel
|
| 125 |
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study
|
von Rundstedt, Friedrich-Carl
|
|
2017
|
|
1 |
p. 35-44
|
artikel
|
| 126 |
Well-being and Perceptions of Supportive Resources among Caregivers of Patients with Bladder Cancer
|
Jung, Ahrang
|
|
|
|
1 |
p. 43-52
|
artikel
|
Tijdschrift beschrijving